Hikma Pharmaceuticals PLC
LSE:HIK

Watchlist Manager
Hikma Pharmaceuticals PLC Logo
Hikma Pharmaceuticals PLC
LSE:HIK
Watchlist
Price: 1 794 GBX -0.83% Market Closed
Market Cap: 4B GBX
Have any thoughts about
Hikma Pharmaceuticals PLC?
Write Note

Hikma Pharmaceuticals PLC
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hikma Pharmaceuticals PLC
Cost of Revenue Peer Comparison

Comparables:
GSK
AZN
VRNA
INDV
DPH

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Hikma Pharmaceuticals PLC
LSE:HIK
Cost of Revenue
-$1.6B
CAGR 3-Years
-10%
CAGR 5-Years
-9%
CAGR 10-Years
-10%
GlaxoSmithKline PLC
LSE:GSK
Cost of Revenue
-ÂŁ8.5B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
-1%
AstraZeneca PLC
LSE:AZN
Cost of Revenue
-$8.7B
CAGR 3-Years
-8%
CAGR 5-Years
-14%
CAGR 10-Years
-5%
Verona Pharma PLC
NASDAQ:VRNA
Cost of Revenue
-$543k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
Cost of Revenue
-$195m
CAGR 3-Years
-18%
CAGR 5-Years
-8%
CAGR 10-Years
-7%
Dechra Pharmaceuticals PLC
LSE:DPH
Cost of Revenue
-ÂŁ331.9m
CAGR 3-Years
-14%
CAGR 5-Years
-13%
CAGR 10-Years
-14%

See Also

What is Hikma Pharmaceuticals PLC's Cost of Revenue?
Cost of Revenue
-1.6B USD

Based on the financial report for Jun 30, 2024, Hikma Pharmaceuticals PLC's Cost of Revenue amounts to -1.6B USD.

What is Hikma Pharmaceuticals PLC's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-10%

Over the last year, the Cost of Revenue growth was -17%. The average annual Cost of Revenue growth rates for Hikma Pharmaceuticals PLC have been -10% over the past three years , -9% over the past five years , and -10% over the past ten years .

Back to Top